Biosynthesis and recovery of selenium nanoparticles and the effects on matrix metalloproteinase-2 expression.
Today, green synthesis of nanoparticles is attracting increasing attention. In the present study, the Bacillus sp. MSh-1 was isolated from the Caspian Sea (located in the northern part of Iran) and identified by various identification tests and 16S ribosomal DNA analysis. The reduction time course study of selenium ion (Se(4+)) reduction by using this test strain was performed in a liquid culture broth. Then, the intracellular NPs (nanoparticles) were released by the liquid nitrogen disruption method and thoroughly purified using an n-octyl alcohol water extraction system. Characterization of the separated NPs on features such as particle shape, size and purity was carried out with different devices. The energy dispersive X-ray and X-ray diffraction patterns showed that the purified NPs consisted of only selenium and are amorphous respectively. In addition, the transmission electron micrograph showed that the separated NPs were spherical and 80-220 nm in size. Furthermore, the cytotoxicity effect of these extracted biogenic selenium (Se) NPs on the fibrosarcoma cell line (HT-1080) proliferation and the inhibitory effect of the Se NPs on MMP-2 (matrix metalloproteinase-2) expression were studied using the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide] assay and gelatin zymography. Biogenic Se NPs showed a moderately inhibitory effect on MMP-2 expression.
Shakibaie
Mojtaba
M
Department of Pharmaceutical Biotechnology and Biotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Khorramizadeh
Mohammad Reza
MR
Faramarzi
Mohammad Ali
MA
Sabzevari
Omid
O
Shahverdi
Ahmad Reza
AR
D000970:Antineoplastic Agents / Q000378:metabolism* / Q000494:pharmacology; D001407:Bacillus / Q000302:isolation & purification / Q000378:metabolism*; D001709:Biotechnology / Q000379:methods*; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D005354:Fibrosarcoma / Q000188:drug therapy; D006801:Humans; D020778:Matrix Metalloproteinase 2 / Q000378:metabolism*; D008969:Molecular Sequence Data; D053758:Nanoparticles / Q000737:chemistry / Q000648:ultrastructure; D012643:Selenium / Q000378:metabolism* / Q000494:pharmacology
D000970:Antineoplastic Agents; D020778:Matrix Metalloproteinase 2; D012643:Selenium